MA49716A - Incorporation de nucléotides non naturels et procédés d'utilisationin vivo - Google Patents

Incorporation de nucléotides non naturels et procédés d'utilisationin vivo

Info

Publication number
MA49716A
MA49716A MA049716A MA49716A MA49716A MA 49716 A MA49716 A MA 49716A MA 049716 A MA049716 A MA 049716A MA 49716 A MA49716 A MA 49716A MA 49716 A MA49716 A MA 49716A
Authority
MA
Morocco
Prior art keywords
incorporation
vivo
procedures
natural nucleotides
nucleotides
Prior art date
Application number
MA049716A
Other languages
English (en)
Inventor
Vivian T Dien
Aaron W Feldman
Floyd E Romesberg
Yorke Zhang
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MA49716A publication Critical patent/MA49716A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07007DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MA049716A 2017-07-11 2018-07-10 Incorporation de nucléotides non naturels et procédés d'utilisationin vivo MA49716A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531329P 2017-07-11 2017-07-11

Publications (1)

Publication Number Publication Date
MA49716A true MA49716A (fr) 2021-04-07

Family

ID=65002437

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049716A MA49716A (fr) 2017-07-11 2018-07-10 Incorporation de nucléotides non naturels et procédés d'utilisationin vivo

Country Status (4)

Country Link
US (1) US20200224234A1 (fr)
EP (1) EP3651774A4 (fr)
MA (1) MA49716A (fr)
WO (1) WO2019014262A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531122A (ja) 2013-08-08 2016-10-06 ザ スクリップス リサーチ インスティテュートThe Scripps Research Institute 非天然ヌクレオチドの取り込みによるインビトロの核酸の部位特異的な酵素標識のための方法
TWI638047B (zh) 2014-04-09 2018-10-11 史基普研究協會 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
DK3475295T3 (da) 2016-06-24 2022-10-24 Scripps Research Inst Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
CN114949240A (zh) 2019-02-06 2022-08-30 新索思股份有限公司 Il-2缀合物及其使用方法
KR20220034109A (ko) 2019-06-14 2022-03-17 더 스크립스 리서치 인스티튜트 반합성 유기체의 복제, 전사 및 번역을 위한 시약 및 방법
CA3150163A1 (fr) 2019-08-15 2021-02-18 Synthorx, Inc. Polytherapies immuno-oncologiques avec des conjugues d'il-2
AU2020337869A1 (en) 2019-08-23 2022-03-03 Synthorx, Inc. IL-15 conjugates and uses thereof
TW202124385A (zh) 2019-09-10 2021-07-01 美商欣爍克斯公司 治療自體免疫疾病之il-2接合物及使用方法
JP2022549931A (ja) * 2019-09-30 2022-11-29 ザ スクリプス リサーチ インスティテュート 真核生物の半合成生物
TW202128996A (zh) * 2019-10-10 2021-08-01 美商史基普研究協會 用於活體內合成非天然多肽的組合物及方法
MX2022005251A (es) 2019-11-04 2022-06-08 Synthorx Inc Conjugados de interleuquina 10 y sus usos.
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
CN116209465A (zh) 2020-06-25 2023-06-02 新索思股份有限公司 用il-2缀合物与抗egfr抗体的免疫肿瘤学组合疗法
IL301611A (en) 2020-10-09 2023-05-01 Synthorx Inc Combined immuno-oncology treatment with pairs of IL-2 and pembrolizumab
EP4225375A1 (fr) 2020-10-09 2023-08-16 Synthorx, Inc. Thérapies immuno-oncologiques avec des conjugués d'il-2
WO2022174101A1 (fr) 2021-02-12 2022-08-18 Synthorx, Inc. Polythérapie contre le cancer de la peau à l'aide de conjugués il-2 et de cemiplimab
TW202302148A (zh) 2021-02-12 2023-01-16 美商欣爍克斯公司 使用il-2接合物和抗pd-1抗體或其抗原結合片段的肺癌組合療法
WO2022256534A1 (fr) 2021-06-03 2022-12-08 Synthorx, Inc. Polythérapie contre le cancer de la tête et du cou comprenant un conjugué d'il-2 et du pembrolizumab
JP2024525866A (ja) 2021-07-16 2024-07-12 アプター バイオ,インク. 遺伝子発現を調節するためのポリヌクレオチド組成物および方法
WO2023122573A1 (fr) 2021-12-20 2023-06-29 Synthorx, Inc. Polythérapie contre le cancer de la tête et du cou comprenant un conjugué d'il-2 et du pembrolizumab
WO2023122750A1 (fr) 2021-12-23 2023-06-29 Synthorx, Inc. Polythérapie contre le cancer avec des conjugués d'il-2 et du cétuximab
WO2024136899A1 (fr) 2022-12-21 2024-06-27 Synthorx, Inc. Thérapie anticancéreuse avec des conjugués d'il-2 et des thérapies par récepteur antigénique chimérique
GB202406362D0 (en) 2024-05-07 2024-06-19 Phytoform Labs Ltd Solanaceae plants having altered morphology

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531122A (ja) * 2013-08-08 2016-10-06 ザ スクリップス リサーチ インスティテュートThe Scripps Research Institute 非天然ヌクレオチドの取り込みによるインビトロの核酸の部位特異的な酵素標識のための方法
TWI638047B (zh) * 2014-04-09 2018-10-11 史基普研究協會 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
US11761007B2 (en) * 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
DK3475295T3 (da) * 2016-06-24 2022-10-24 Scripps Research Inst Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
TWI821192B (zh) * 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法

Also Published As

Publication number Publication date
WO2019014262A1 (fr) 2019-01-17
EP3651774A1 (fr) 2020-05-20
US20200224234A1 (en) 2020-07-16
EP3651774A4 (fr) 2021-07-07

Similar Documents

Publication Publication Date Title
MA49716A (fr) Incorporation de nucléotides non naturels et procédés d'utilisationin vivo
MA49578A (fr) Incorporation de nucléotides non naturels et procédés associés
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA43822A (fr) Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
ZA201704976B (en) Oral care compositions and methods of use
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
IL257663B (en) Oral treatment compounds and methods of using them
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
ZA201807359B (en) Oral care compositions and methods of use
ZA201903432B (en) Oral care compositions and methods of use
ZA201801012B (en) Oral care compositions and methods of use
MA45290A (fr) Procédés et compositions d'agents biologiquement actifs
MA51430A (fr) Compositions de paire de bases non naturelles et procédés d'utilisation
MA42685A (fr) Synthèse de chlorhydrate de lévométhadone ou de chlorhydrate de dextrométhadone et leurs méthodes d'utilisation
SG11201912185XA (en) Three dimensional tissue compositions and methods of use
MA46586A (fr) Compositions de terlipressine et leurs procédés d'utilisation
ZA201902268B (en) Oral care compositions and methods of use
MA54412A (fr) Traitement d'excès de graisse hépatique et/ou viscérale
MA43730A (fr) Malassezine et analogues correspondants en tant qu'agents d'éclaircissement de la peau
EP2707486A4 (fr) Diagnostic et traitement de l'ataxie de friedreich
MA42497A (fr) Procédés et compositions pour la régulation sélective de l'expression protéique
MA50829A (fr) Exclusion d'exon induite pat technologie antisens dans le collagène de type vii
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
MA43178A (fr) Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci